1-(2,3-Anhydro-beta-D-lyxofuranosyl)cytosine derivatives as potential inhibitors of the human immunodeficiency virus.
We report here that 1-(2,3-anhydro-beta-D-lyxofuranosyl)cytosine has activity against the human immunodeficiency virus in vitro. A number of 2',3'-anhydro-beta-D-lyxofuranosyl nucleoside derivatives were prepared, but none had the activity of the title compound. New efficient procedures were developed for the synthesis of 3'-deoxy-3'-alkyl- and 3'-deoxy-beta-D-arabinosylpyrimidine derivatives.
Webb
T R
TR
Genentech, Inc., South San Francisco, California 94080.
Mitsuya
H
H
Broder
S
S
D003504:Ancitabine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D003561:Cytarabine / Q000031:analogs & derivatives*; D003562:Cytidine; D006678:HIV / Q000187:drug effects*; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D013936:Thymidine / Q000031:analogs & derivatives / Q000494:pharmacology; D014498:Uracil; D015215:Zidovudine
D003561:Cytarabine; C056442:1-(2,3-anhydrolyxofuranosyl)cytosine; D015215:Zidovudine; D014498:Uracil; D003562:Cytidine; D003504:Ancitabine; D013936:Thymidine